Patents by Inventor Shahin Raffi

Shahin Raffi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reprogramming of human endothelium into hematopoietic multi-lineage progenitors by defined factors
    Patent number: 10113149
    Abstract: The invention is directed to generation of hematopoietic multi-lineage progenitors (HMLPs) from endothelial cells (ECs) by effecting forced expression of certain transcription factors in the ECs and culturing the ECs in serum free media in the presence of endothelial feeder cells. The HMLPs generated in accordance with this invention can produce erythroid, lymphoid, myeloid, and megakaryocyte cells. These generated HMLPs can be used in therapeutic treatment of disorders including hematopoietic conditions.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: October 30, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Vladislav M. Sandler, Shahin Raffi
  • REPROGRAMMING OF HUMAN ENDOTHELIUM INTO HEMATOPOIETIC MULTI-LINEAGE PROGENITORS BY DEFINED FACTORS
    Publication number: 20150361398
    Abstract: The invention is directed to generation of hematopoietic multi-lineage progenitors (HMLPs) from endothelial cells (ECs) by effecting forced expression of certain transcription factors in the ECs and culturing the ECs in serum free media in the presence of endothelial feeder cells. The HMLPs generated in accordance with this invention can produce erythroid, lymphoid, myeloid, and megakaryocyte cells. These generated HMLPs can be used in therapeutic treatment of disorders including hematopoietic conditions.
    Type: Application
    Filed: January 15, 2014
    Publication date: December 17, 2015
    Applicant: CORMELL UNIVERSITY
    Inventors: Vladislav M. SANDLER, Shahin RAFFI
  • METHODS FOR DEVELOPING ENDOTHELIAL CELLS FROM PLURIPOTENT CELLS AND ENDOTHELIAL CELLS DERIVED
    Publication number: 20120301443
    Abstract: Disclosed herein is a method for developing human endothelial cells (ECs) from human embryonic stem cells (ESCs). The method is based on inhibition of TGF signaling following mesoderm induction and during vascular differentiation of hESC-derived cells. Also disclosed herein is a substantially pure and stable population of ECs that maintains a high degree of proliferation and phenotypic homogeneity for extended culture periods. Related pharmaceutical compositions and therapeutic methods are also disclosed. A reporter hESC line useful for tracking the development of ECs is also provided.
    Type: Application
    Filed: December 23, 2010
    Publication date: November 29, 2012
    Applicant: CORNELL UNIVERSITY
    Inventors: Shahin Raffi, Daylon James